# AI-Enhanced Gene Editing Therapies ElevateBio is Partnering with Amazon Web Services By Kalin Ned | Published 2025-03-10 | Tech Source: Trend Hunter, https://www.trendhunter.com/trends/gene-editing-therapies References: [globenewswire](https://www.globenewswire.com/news-release/2025/03/10/3039578/0/en/ElevateBio-Collaborates-with-AWS-to-Broaden-the-Potential-of-CRISPR-Gene-Editing-Therapies-with-Generative-AI.html) & [elevate.bio](https://elevate.bio/)  ElevateBio has announced a multi-year collaboration with Amazon Web Services to harness generative artificial intelligence for advancing [CRISPR gene editing therapies](https://www.trendhunter.com/trends/genome-editing-platform). This partnership aims to accelerate the discovery, design, and optimization of CRISPR-based treatments for a wide range of genetic diseases, including complex monogenic and polygenic disorders. By leveraging [Amazon Web Services'](https://www.trendhunter.com/trends/aws-for-games) cloud infrastructure, which includes SageMaker for machine learning and analytics, ElevateBio’s [Life Edit](https://www.trendhunter.com/trends/optional-multiplayer-support) division will analyze its extensive library of CRISPR systems and proprietary experimental data to identify and optimize novel gene editing therapies. The integration of AI with Life Edit’s gene editing platform, which supports base editing and reverse transcriptase editing, will enable the development of both ex vivo and in vivo therapies. This collaboration builds on a proof-of-concept project that demonstrated enhanced protein discovery capabilities and reduced costs using Amazon Web Services' advanced computing resources. Image Credit: ElevateBio x Amazon Web Services ## Trend Insights (Trend Hunter) - Score: 6.5/10 - Popularity: 77% | Activity: 82% | Freshness: 36% - Audience gender: 50% men, 50% women - Primary generations: Millennial, Gen X - Top markets: North America ## Categories [Trend Hunter](https://www.trendhunter.com/trends) > [Tech](https://www.trendhunter.com/tech) > [AI](https://www.trendhunter.com/ai) ## Key Themes ### Key Themes Behind This Trend - **AI-powered Gene Editing:** Transformative potential lies in AI's ability to streamline the creation and efficiency of CRISPR tools, leading to more targeted and effective gene editing applications. - **Cloud-based Biomedical Research:** The collaboration highlights the trend of utilizing cloud infrastructure to support expansive data analysis and machine learning models in biomedical research. - **Generative AI in Therapeutic Development:** Generative AI is being increasingly incorporated to accelerate the development of innovative gene therapies addressing both simple and complex genetic disorders. ### Where This Applies - **Biotechnology:** The biotechnology industry stands to benefit from integrating AI to enhance the precision and speed of gene therapy development. - **Cloud Computing:** Cloud computing platforms are becoming integral in supporting vast biomedical datasets and computational tasks required for advanced research. - **Pharmaceuticals:** Pharmaceutical companies can leverage AI-driven gene editing to innovate their pipelines with faster and more personalized therapeutic options. ## Related on Trend Hunter - [AI Drug Platforms](https://www.trendhunter.com/trends/insilico-medicine-mmai.md) - [AI-Enhanced Breast Cancer Treatments](https://www.trendhunter.com/trends/sophia-genetics.md) - [Generative AI Accelerator Programs](https://www.trendhunter.com/trends/accelerator-program.md) - [Upskilling AI Initiatives](https://www.trendhunter.com/trends/genpact-and-microsoft.md) - [AI Kidney Therapies](https://www.trendhunter.com/trends/nephrogen.md) - [AI Supplement Recommendation Platforms](https://www.trendhunter.com/trends/supplement-recommendation-platform.md) - [Biomolecular AI Foundation Models](https://www.trendhunter.com/trends/biomolecular-research.md) - [Strategic Therapeutics Projects](https://www.trendhunter.com/trends/protein-therapeutics.md) - [Biology-Focused AI Models](https://www.trendhunter.com/trends/bioptimus.md)